Phar­ma com­pa­nies ques­tion new EU in­cen­tives as re­vamp ad­vances

Mem­bers of a com­mit­tee for the Eu­ro­pean Par­lia­ment on Tues­day signed off on a new leg­isla­tive over­haul that aims to make their con­ti­nent more at­trac­tive for phar­ma com­pa­nies, but that drug com­pa­nies have said may end up do­ing the op­po­site.

The new di­rec­tive and reg­u­la­tion would make phar­ma com­pa­nies el­i­gi­ble for a min­i­mum reg­u­la­to­ry da­ta pro­tec­tion pe­ri­od — where oth­er com­pa­nies can’t ac­cess their prod­uct da­ta — of sev­en and a half years. They’d al­so re­ceive two years of mar­ket pro­tec­tion dur­ing which gener­ics or biosim­i­lars couldn’t be sold.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER